Angiogenesis
Results of VEGF Trap (Aflibercept) Highlighted at ASCO 2007 Annual Meeting
Published in Medical Verdicts and Law Weekly, June 21st, 2007
Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced encouraging preliminary results from two Phase II studies in advanced ovarian cancer and lung cancer with aflibercept (VEGF Trap), an anti- angiogenic agent targeting Vascular Endothelial Growth Factor. Aflibercept (VEGF Trap) is being developed by Regeneron in collaboration with sanofi- aventis. The companies will present data from the lung cancer study tomorrow.
These are the first reported results from a late-stage development program consisting of single-agent studies and planned Phase III trials in combination with common chemotherapy regimens in several...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
More Articles from Medical Verdicts and Law Weekly
- AARP New York
Long Island Seniors Rally for Rx Affordable Prescription Drugs and Cell Phone Protections - American Medical Informatics Association
AMIA and AHIMA Applaud House Passage of H.R. 1467, the '10,000 Trained by 2010 Act' - American Nurses Association
ANA and NYSNA Condemn Exploitation of Filipino Registered Nurses - Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals, Inc. Announces Exercise of Initial Purchasers' Option for Additional $75 Million of Convertible Senior Notes - Aneurysm
Rudy Boesch: Still Living Life to the Fullest as a ``Survivor'' in More Ways Than One - ArQule, Inc.
ArQule Announces Offering of Common Stock - More from this issue of Medical Verdicts and Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
